Factor 8 Ehl denied for failing step therapy by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for factor 8 ehl are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UnitedHealthcare Denied Your Extended Half-Life Factor VIII — Step Therapy

UnitedHealthcare's step therapy (also called "fail first") policy for Factor VIII requires that a patient demonstrate an adequate trial of a standard half-life (SHL) Factor VIII product before it will authorize coverage of the more expensive extended half-life (EHL) formulation. A step-therapy denial means UHC does not have documentation on file that this step has been completed — or that it believes the required trial was inadequate. Step therapy is increasingly regulated, and many states now have laws limiting its use in certain clinical circumstances.

## Why This Denial Is Appealable

Step therapy for hemophilia A is frequently overturned on appeal for several reasons. First, many patients with hemophilia A have been on standard half-life Factor VIII for years and have documented clinical history showing why the EHL formulation is medically necessary (e.g., persistent breakthrough bleeds on prophylaxis, joint damage progression, vein access problems, intolerable infusion burden). Second, switching a patient who is already stable on EHL back to SHL solely to satisfy an insurer's step requirement can cause direct clinical harm. Third, some state step-therapy laws explicitly prohibit requiring a step when the patient has already tried and failed — or would be harmed by — the step drug.

## Federal Appeal Framework

• Internal appeal: File within 180 days. If your infusion schedule cannot be safely interrupted, request expedited review (72-hour turnaround).
• External review (ACA §2719): After final internal denial, request independent external review within the four-month window. External reviewers will evaluate whether UHC's step requirement is clinically appropriate for this patient's documented history.
• ERISA §503: Employer plan members are entitled to see the specific step-therapy criteria and clinical guidelines UHC applied.
• State step-therapy protections: If you are in a state with a step-therapy exception law, cite it in your appeal. Many state laws require an exception when the required step drug is contraindicated, previously tried and failed, or when the prescriber certifies that the step drug would cause adverse clinical consequences.

## Documentation to Gather

1. Prior Factor VIII treatment history — a complete chronological list of all Factor VIII products used, with start/end dates, doses, frequency, and clinical outcome (breakthrough bleeds, ABR, joint assessments). 2. Evidence of step completion or failure — infusion logs, pharmacy dispensing records, bleeding diaries, or clinical notes documenting inadequate response on standard half-life Factor VIII. 3. Clinical rationale for EHL specifically — prescriber letter explaining why EHL is medically necessary rather than SHL: PK data, infusion burden impact on adherence, vein access issues, or persistent joint bleeds. 4. Joint imaging or orthopedic assessment — if joint disease has progressed, imaging reports support the urgency of optimizing prophylaxis. 5. UHC's step-therapy policy — print the current policy and identify the exact step requirements and exception criteria. 6. State law reference — if your state has a step-therapy exception statute, cite it by name in the appeal.

## Criteria-Mapping Structure

Address each step-therapy criterion directly: - Column A: UHC's stated step requirement (copy exact language from the coverage policy). - Column B: The chart fact or record that shows the step was completed, failed, or that an exception applies (e.g., clinical harm, prior failure, state law exception).

If the patient has never tried SHL Factor VIII, explain the clinical reason the prescriber bypassed the step and why requiring it now would be medically inappropriate given the patient's current clinical status.